This site is intended only for healthcare professionals in Hong Kong SAR.

Our medicinesOur medicinesBesponsaCibinqoCresembaEliquisEnbrelIbranceLorviquaNgenlaNurtecPaxlovidPrevenar20PristiqTalzennaVizimproVyndamaxXeljanzZaviceftaSee All productsPfizer Hong Kong Price ListTherapy areasTherapy areasMultiple MyelomaNon-Small-Cell Lung CancerRespiratory Syncytial VirusTransthyretin AmyloidosisSearch

Menu

Close

Sign InLog Out
Explore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information

Menu

Close

Clinical efficacy & safetyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)SafetySafety overviewPooled ARsPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresGI and liver toxicitiesEffect of IBRANCE® on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyReal-world evidenceWhat are RWD and RWE?IBRANCE® global evidenceCharacteristics of RWEDefinition of RWE and RWDValue and importance of RWEIBRANCE® RWE initiativesP-REALITYFlatiron databaseStudy design Patient characteristicsReal-world progression-free survivalOverall survivalStudy strengths and limitationsMADELINEMADELINE mobile applicationMADELINE study designMADELINE patient characteristicsMADELINE physician-reported AEsMADELINE patient-reported outcomesMADELINE study limitationsMADELINE summaryDosingRecommended dosing scheduleRecommended dose modifications for AEsMonitoringOne scheduled monitoring provision

Patient safety is of paramount importance throughout the life cycle of a medicine - and pharmaceutical companies have ethical and regulatory responsibilities to monitor the safety of the products they sell for as long as they are used by consumers anywhere in the world. The Drug Safety Unit at Pfizer Corporation Hong Kong Limited. address product experience reports including adverse events. If you have any experience pertinent to the above, please contact us at (852) 2811 9711 as soon as possible.

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals resident in to Hong Kong. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.com.hk

 

The information provided in this site is intended only for Health Professionals who reside in Hong Kong, and the products discussed herein may have different product labeling in different countries/regions. The site is for information purpose only, and nothing herein shall be construed as providing any kind of medical advice or recommendation or product promotion. Pfizer Corporation Hong Kong Limited is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.

 

Copyright© 2023 Pfizer Corporation Hong Kong Limited. All rights reserved.

PP-UNP-HKG-0116 MAY 2023
You are leaving the PfizerPro Hong Kong website
​
You are being directed to a third-party website:

Please note that this third-party website is not controlled by PfizerPro Hong Kong or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
​​​​​​​
PP-UNP-HKG-0076. May 2023​​​​​​​